title: [Safety of different sequential immunization schedules of inactivated poliovirus vaccine and oral poliovirus vaccine primary vaccination].
abstract: OBJECTIVE
  To evaluate safety of different sequential immunization schedules of inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) primary vaccination.
  
  
  METHODS
  Infants of 2 months old (60-89 days) selected in Beijing, were assigned to four groups, 1 dose IPV plus 2 doses OPV (I-O-O), 2 doses IPV plus 1 dose OPV(I-I-O), 3 doses IPV (I-I-I), and 3 doses OPV (O-O-O), and were vaccinated at the age of 2, 3, 4 months, from 2009 to 2011. The frequencies of systemic as well as local injection site reactions after every dose were recorded and calculated. A total of 553 infants were enrolled in the study and 89 infants were quit, 1492 diseases were observed.
  
  
  RESULTS
  The incidence of adverse events in I-O-O, I-I-O, I-I-I, O-O-O were 22.9% (94/410), 18.4% (60/327), 22.0% (78/354) and 17.7% (71/401) with no statistical differences (χ(2) = 4.84, P = 0.184). Dose 1 (22.7% (32/141)-35.3% (54/153) ) was more frequently than dose 2 and dose 3. No serious adverse events (SAE) were reported during the study. The incidence of systemic adverse reactions in I-O-O, I-I-O, I-I-I, O-O-O were 21.5% (88/410), 17.7% (58/327) , 20.1% (71/354) and 17.7% (71/401) with no statistical differences (χ(2) = 2.53, P = 0.472). Abnormal crying were the most frequency reactions (7.2% (29/401)-11.3% (37/327) ) in 4 groups. Rarely severe reactions were observed of abnormal crying, somnolence, irritability and mild or medium reactions occurred in other symptoms. Local adverse reactions such as injection site pain, scleroma and swelling were reported by 2.2% (5/229)-5.6% (22/393) ,0-0.9% (2/229) and 0-1.0% (4/393) in I-O-O,I-I-O and I-I-I, and most reactions were mild.
  
  
  CONCLUSIONS
  Three IPV immunization and IPV/OPV sequential immunization as well as three OPV immunization demonstrated safe.
authors.affiliation: Department of Immunization,Beijing Centre for Disease Control and Prevention,Beijing 100013, China.
authors.forename: Zhu-jia-zi
authors.initials: ZJ
authors.lastname: Zhang
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Hai-hong
authors.initials: HH
authors.lastname: Wang
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Zhao-qi
authors.initials: ZQ
authors.lastname: Ning
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.forename: Ping
authors.initials: P
authors.lastname: Chu
authors.forename: Yan-tao
authors.initials: YT
authors.lastname: Xie
authors.forename: Xiao-mei
authors.initials: XM
authors.lastname: Li
authors.forename: Dong-lei
authors.initials: DL
authors.lastname: Liu
authors.affiliation: Email:lulibj@sina.com.
authors.forename: Li
authors.initials: L
authors.lastname: Lu
mesh_terms: D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000009:adverse effects*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D011054:Poliovirus Vaccine, Inactivated; D014613:Vaccines, Attenuated